carbidopa


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to carbidopa: Entacapone

carbidopa

 [kahr-bĭ-do´pah]
an inhibitor of the decarboxylation of levodopa in peripheral tissues; it does not cross the blood-brain barrier and is used in combination with levodopa to control the symptoms of parkinson's disease. In the presence of carbidopa, levodopa enters the brain in larger quantities, thus avoiding the need for excessively high doses of levodopa.

car·bi·do·pa

(kar'bi-dō'pă),
A dopa decarboxylase inhibitor that does not enter the brain used in conjunction with levodopa in the treatment of Parkinson disease to reduce L-dopa dosage and mitigate side effects.

carbidopa

/car·bi·do·pa/ (kahr″bĭ-do´pah) an inhibitor of decarboxylation of levodopa in extracerebral tissues, used in combination with levodopa as an antiparkinsonian agent.

carbidopa

(kär′bĭ-dō′pə)
n.
A drug, C10H14N2O4, that increases the availability of L-dopa to the brain and is administered with L-dopa to treat Parkinson's disease.

carbidopa

[kär′bidō′pə]
a dopa decarboxylase inhibitor that cannot cross the blood-brain barrier.
indication It is prescribed in combination with levodopa in the treatment of idiopathic Parkinson's disease because it inhibits the degradation of levodopa in the periphery, thereby permitting a larger percentage of orally administrated doses to enter the brain.
contraindications Glaucoma, hypertension, use of a monoamine oxidase inhibitor within the past 14 days, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the most serious adverse reactions are GI bleeding, cardiac irregularity, hemolytic anemia, tardive dyskinesia, mental depression, blurred vision, and activation of malignant melanoma.

car·bi·do·pa

(kahr'bi-dō'pă)
A dopa decarboxylase inhibitor that does not enter the brain used in conjunction with levodopa in the treatment of parkinsonism to reduce L-dopa dosage and mitigate side effects.

carbidopa

A drug that prevents the breakdown of the drug levodopa in the body and thus enhances its action in PARKINSON'S DISEASE. See also BENSERAZIDE. A brand name is Sinemet.

carbidopa

formulation of dopamine, used to control symptoms of Parkinson's disease
References in periodicals archive ?
As most patients in these studies were treated with a combination of L-DOPA and carbidopa, it is possible that one or both of these drugs could exhibit anti-cancer properties and contribute to the lower incidence of cancer observed in these patients.
7% between 1976 and 2011, when carbidopa was first introduced.
The preliminary results indicate that the bi-layer tablet formulation provided a sustained levodopa exposure that was consistent with XenoPort's prior open-label trial that utilized separate extended-release XP21279 and commercially-available carbidopa tablets.
Biopharmaceutical company Intec Pharma Ltd (NASDAQ:NTEC)(TASE:NTEC) reported on Wednesday the receipt of a Certificate of Grant of a Hong Kong patent for an Accordion Pill containing certain drugs, including the combination of Carbidopa and Levodopa, from the Patent Registry Intellectual Property Department of Hong Kong.
Carbidopa and levodopa are the generic versions of Du Pont Pharmaceuticals' Sinemet.
Limited Tenders are invited for Supply Of Tab Levodopa250 mg + Carbidopa 25 mg, Inj Erythropoietin Human recombinant 6000 IU, Tab Ursodeoxycholic Acid 600MG
DRUG DOSAGE COST/DAY [*] DOPAMINE PRECURSOR carbidopa and Start at 25 mg of carbidopa $1.
It is being studied as a treatment for symptoms of OFF periods in people with Parkinson's taking an oral carbidopa / levodopa regimen.
RYTARY contains immediate release and extended-release beads, with a specific amount of carbidopa and levodopa in a 1:4 ratio, and provides both initial and extended levodopa plasma concentrations after a single dose.
These generic Carbidopa, Levodopa and Entacapone tablets contain Carbidopa, Levodopa and Entacapone 25/100/200 mg, and 37.
Tenders are invited for Tab Carbidopa 50Mg Plus Levodopa 200Mg Cr
XenoPort has initiated a Phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetics of a new bi-layer formulation of sustained release XP21279 and carbidopa in patients with Parkinson's disease.